DEA Completes Scheduling Actions for Synthetic Cannabinoids and Zulresso; Removes Opioid Treatment Drug From Control

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Scheduling Actions

DEA Completes Scheduling Actions for Synthetic Cannabinoids and Zulresso; Removes Opioid Treatment Drug From Control

Ken Baumgartner

January 27, 2020 at 23:52:52 ET

The Drug Enforcement Administration on Jan. 24 published notices to complete certain scheduling actions and to remove from control a drug used to treat opioid addiction. One final rule (85 Fed. Reg. 4211) placed in Schedule I six synthetic cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA, and MDMB-FUBINACA) that since 2017 have been controlled in Schedule I under... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

DEA Completes Scheduling Actions for Synthetic Cannabinoids and Zulresso; Removes Opioid Treatment Drug From Control

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT